SCHEMBL3486770

SCHEMBL3486770

COC(=O)c1c(OC)ccc2c1/C(=C/c1[nH]c(C)cc1C)C(=O)N2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 10/20 0.55
CHEK1 O14757 1/20 0.53
KDR P35968 5/20 0.52
PDPK1 O15530 2/20 0.52
TLK2 Q86UE8 1/20 0.52
PDGFRB P09619 4/20 0.51
FLT3 P36888 3/20 0.49
ALK Q9UM73 3/20 0.49
CSF1R P07333 2/20 0.49
FGFR1 P11362 2/20 0.49
SRC P12931 2/20 0.49
FLT1 P17948 2/20 0.49
FGFR3 P22607 2/20 0.49
MAPK1 P28482 2/20 0.49
FLT4 P35916 2/20 0.49
AURKB Q96GD4 2/20 0.49
PDGFRA P16234 2/20 0.49
MEN1 O00255 1/20 0.49
NPC1 O15118 1/20 0.49
GMNN O75496 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3486324 0.91 RET (0.57) RETCHEK1KDRPDPK1TLK2
SCHEMBL3486051 0.91 RET (0.53) RETCHEK1KDRPDPK1TLK2
SCHEMBL4064004 0.81 ALK (0.55) RETKDRPDGFRBFLT3ALK
SCHEMBL5362637 0.77 TLK2 (0.77) RETKDRPDPK1TLK2PDGFRB
SCHEMBL13432277 0.73 RET (0.69) RETKDRPDPK1TLK2PDGFRB
SCHEMBL3953189 0.73 KDR (0.69) RETCHEK1KDRPDPK1TLK2
SCHEMBL5366277 0.72 RET (0.64) RETCHEK1KDRPDPK1TLK2
SCHEMBL14301681 0.72 RET (0.60) RETKDRPDPK1TLK2PDGFRB
SCHEMBL5470645 0.72 RET (0.60) RETKDRPDPK1TLK2PDGFRB
SCHEMBL5470642 0.72 RET (0.60) RETKDRPDPK1TLK2PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035251-A1 BioMarkers for the Progression of Alzheimer's Disease HE YUNSHENG 2010-02-11 US disclosed
EP-2035582-A2 BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE Novartis AG (CH) 2009-03-18 EP disclosed
WO-2007149798-A2 BIOMARKERS FOR THE PROGRESSION OF ALZHEIMER'S DISEASE NOVARTIS AG (CH) 2007-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035251-A1 BioMarkers for the Progression of Alzheimer's Disease LRRK2, PSEN2, CLK2 RET 1702/4885CHEK1 52/4885KDR 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.